Nahush Pharmaceuticals is a startup in healthcare sector. The company was constituted on 18th of July 2023. The company is located in Patna, Bihar. The first project Nahush Pharmaceuticals is involved in is a Blood Stopping (Hemostatic) Bandage.
The Prolem we are trying to solve: Deaths caused due to uncontrolled hemmorage (blood loss).
Uncontrolled haemorrhage remains the leading cause of pre-hospital trauma death in civilians, natural disasters, and army fields.Excessive bleeding occurs before the patient reaches the hospital setting, especially in road traffic accidents, as well as in army soldiers where the health care facility is often far off from the site of injury.
In 2000, the World health organization (WHO) estimated that injury resulted in 9% of the global mortality and 12% of the worldwide disease burden.Worldwide, severe trauma results in the death of over 5 million persons annually and was projected to surpass 8 million annually by the year 2020.Hemorrhage accounts for approximately 35% of the mortality from these traumatic injuries, second only to central nervous system (CNS) injury.
Up to half of the deaths resulting from hemorrhage occur before reaching definitive care. Violence is the leading cause of these injuries, and traffic collisions are second. In 2015, the national trauma institute estimated that in the civilian arena, "severe bleeding accounts for greater than 35% of pre-hospital deaths.
Source: Hemorrhage Control ; Eric R. Donley; Sunil Munakomi; Joshua W. Loyd. https://www.ncbi.nlm.nih.gov/books/NBK535393/InstaStop acts as a lifesaver in situations involving road accidents and injuries among paramilitary and military personnel. These individuals often find themselves in remote areas, far removed from immediate medical assistance. When injuries occur, the transportation process to reach a hospital can result in substantial blood loss, leading to tragic consequences and the loss of invaluable lives. Our product, InstaStop, addresses this critical issue effectively. Its portable nature makes it an essential addition to first aid kits, ensuring that it is readily available when needed. By applying InstaStop directly to the injury site, bleeding can be swiftly controlled. This will enable the injured to be transported to a medical facility without experiencing significant blood loss. This intervention is pivotal, as it increases the likelihood of survival and ensures that these courageous individuals receive the prompt medical attention they require. InstaStop serves as a vital tool in saving lives and minimizing the impact of injuries sustained in challenging environments.
InstaSTOP utilizes Chloro-Chitosan as active ingadiant.
platelets, the primary agents in blood clotting, exhibit a negative charge on their surface, while our molecule carries a positive charge. This polarity sets the stage for an interaction that is crucial for the healing process.
Secondly, as blood exits the body through an injury, a critical step emerges: the implementation of a mechanism capable of extracting water while retaining essential particles. This function is expertly executed by the hydrogel component of our approach. By effectively removing excess water, this component facilitates an increase in the concentration of platelets at the site of injury, thus accelerating the healing process.
Moreover, the positively charged nature of our molecule serves as a beacon for platelets, prompting them to align themselves appropriately at the injury site. This alignment is instrumental in initiating the natural cascade of events that culminate in the healing of the wound.
In essence, our approach mirrors the body’s innate healing mechanisms. Just as setting a fractured bone enables the body to take over the healing process, our method involves merely removing water, aligning platelets, and allowing the body’s natural processes to drive the healing forward.
To ensure compliance with various regulations and approval by CDSCO animal trials are being conducted. Human trials will commence after animal trials. NPPL is being guided by ICMR through MedTech Mitra initiative in the studies being conducted.
MFG/TL/MD/2024/000114. 'Licence to Manufacture Medical Devices for the purpose of Clinical Investigation' granted by CDSCO.
Attended Startup Mahakumbh from March 18-20 at Bharat Mandapam, New Delhi. An event attended by thousands of StartUps and Investors.
Please Contact